Voyager Therapeutics has hit pause on a preclinical Alzheimer’s disease program just eight months after unveiling the asset. The neurology biotech announced back in July 2025 that it was adding a new ...
LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company ...
Voyager Technologies (NYSE:VOYG) appointed Shoshanna Moody as Chief Administrative Officer. Moody is tasked with supporting operational scale and regulatory compliance as the company expands into ...
Voyager Technologies, Inc. recently reported fourth-quarter 2025 sales of US$46.65 million and a net loss of US$30.22 million, alongside full-year 2025 sales of US$166.42 million and a net loss of ...
LEXINGTON, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it has decided to ...
- New program combines IV-delivered TRACER™ capsid with bifunctional payload to silence APOE in carriers of the high-risk APOE4 variant while delivering the protective APOE2 variant - - Voyager’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results